<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">34390052</PMID><DateCompleted><Year>2021</Year><Month>09</Month><Day>24</Day></DateCompleted><DateRevised><Year>2021</Year><Month>09</Month><Day>24</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1460-9568</ISSN><JournalIssue CitedMedium="Internet"><Volume>54</Volume><Issue>6</Issue><PubDate><Year>2021</Year><Month>Sep</Month></PubDate></JournalIssue><Title>The European journal of neuroscience</Title><ISOAbbreviation>Eur J Neurosci</ISOAbbreviation></Journal><ArticleTitle>Riluzole does not ameliorate disease caused by cytoplasmic TDP-43 in a mouse model of amyotrophic lateral sclerosis.</ArticleTitle><Pagination><StartPage>6237</StartPage><EndPage>6255</EndPage><MedlinePgn>6237-6255</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/ejn.15422</ELocationID><Abstract><AbstractText>Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease commonly treated with riluzole, a small molecule that may act via modulation of glutamatergic neurotransmission. However, riluzole only modestly extends lifespan for people living with ALS, and its precise mechanisms of action remain unclear. Most ALS cases are characterised by accumulation of cytoplasmic TAR DNA binding protein of 43&#x2009;kDa (TDP-43), and understanding the effects of riluzole in models that closely recapitulate TDP-43 pathology may provide insights for development of improved therapeutics. We therefore investigated the effects of riluzole in female transgenic mice that inducibly express nuclear localisation sequence (NLS)-deficient human TDP-43 in neurons (NEFH-tTA/tetO-hTDP-43&#x394;NLS, 'rNLS8', mice). Riluzole treatment from the first day of hTDP-43&#x394;NLS expression did not alter disease onset, weight loss or performance on multiple motor behavioural tasks. Riluzole treatment also did not alter TDP-43 protein levels, solubility or phosphorylation. Although we identified a significant decrease in GluA2 and GluA3 proteins in the cortex of rNLS8 mice, riluzole did not ameliorate this disease-associated molecular phenotype. Likewise, riluzole did not alter the disease-associated atrophy of hindlimb muscle in rNLS8 mice. Finally, riluzole treatment beginning after disease onset in rNLS8 mice similarly had no effect on progression of late-stage disease or animal survival. Together, we demonstrate specific glutamatergic receptor alterations and muscle fibre-type changes reminiscent of ALS in female rNLS8 mice, but riluzole had no effect on these or any other disease phenotypes. Future targeting of pathways related to accumulation of TDP-43 pathology may be needed to develop better treatments for ALS.</AbstractText><CopyrightInformation>&#xa9; 2021 Federation of European Neuroscience Societies and John Wiley &amp; Sons Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wright</LastName><ForeName>Amanda L</ForeName><Initials>AL</Initials><Identifier Source="ORCID">0000-0001-7141-6212</Identifier><AffiliationInfo><Affiliation>Centre for Motor Neuron Disease Research, Macquarie Medical School, Faculty of Medicine, Health and Human Sciences, Macquarie University, Sydney, New South Wales, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Della Gatta</LastName><ForeName>Paul A</ForeName><Initials>PA</Initials><Identifier Source="ORCID">0000-0003-2231-8370</Identifier><AffiliationInfo><Affiliation>Institute for Physical Activity and Nutrition (IPAN), School of Exercise and Nutrition Sciences, Deakin University, Geelong, Victoria, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Le</LastName><ForeName>Sheng</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Centre for Motor Neuron Disease Research, Macquarie Medical School, Faculty of Medicine, Health and Human Sciences, Macquarie University, Sydney, New South Wales, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Berning</LastName><ForeName>Britt A</ForeName><Initials>BA</Initials><AffiliationInfo><Affiliation>Centre for Motor Neuron Disease Research, Macquarie Medical School, Faculty of Medicine, Health and Human Sciences, Macquarie University, Sydney, New South Wales, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neurodegeneration Pathobiology Laboratory, Queensland Brain Institute, The University of Queensland, St Lucia, Queensland, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mehta</LastName><ForeName>Prachi</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Centre for Motor Neuron Disease Research, Macquarie Medical School, Faculty of Medicine, Health and Human Sciences, Macquarie University, Sydney, New South Wales, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jacobs</LastName><ForeName>Kelly R</ForeName><Initials>KR</Initials><AffiliationInfo><Affiliation>Centre for Motor Neuron Disease Research, Macquarie Medical School, Faculty of Medicine, Health and Human Sciences, Macquarie University, Sydney, New South Wales, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gul</LastName><ForeName>Hossai</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Centre for Motor Neuron Disease Research, Macquarie Medical School, Faculty of Medicine, Health and Human Sciences, Macquarie University, Sydney, New South Wales, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>San Gil</LastName><ForeName>Rebecca</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0001-5725-5512</Identifier><AffiliationInfo><Affiliation>Centre for Motor Neuron Disease Research, Macquarie Medical School, Faculty of Medicine, Health and Human Sciences, Macquarie University, Sydney, New South Wales, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neurodegeneration Pathobiology Laboratory, Queensland Brain Institute, The University of Queensland, St Lucia, Queensland, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hedl</LastName><ForeName>Thomas J</ForeName><Initials>TJ</Initials><AffiliationInfo><Affiliation>Centre for Motor Neuron Disease Research, Macquarie Medical School, Faculty of Medicine, Health and Human Sciences, Macquarie University, Sydney, New South Wales, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neurodegeneration Pathobiology Laboratory, Queensland Brain Institute, The University of Queensland, St Lucia, Queensland, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Riddell</LastName><ForeName>Winonah R</ForeName><Initials>WR</Initials><AffiliationInfo><Affiliation>Centre for Motor Neuron Disease Research, Macquarie Medical School, Faculty of Medicine, Health and Human Sciences, Macquarie University, Sydney, New South Wales, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Watson</LastName><ForeName>Owen</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Centre for Motor Neuron Disease Research, Macquarie Medical School, Faculty of Medicine, Health and Human Sciences, Macquarie University, Sydney, New South Wales, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Keating</LastName><ForeName>Sean S</ForeName><Initials>SS</Initials><AffiliationInfo><Affiliation>Neurodegeneration Pathobiology Laboratory, Queensland Brain Institute, The University of Queensland, St Lucia, Queensland, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Venturato</LastName><ForeName>Juliana</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Neurodegeneration Pathobiology Laboratory, Queensland Brain Institute, The University of Queensland, St Lucia, Queensland, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chung</LastName><ForeName>Roger S</ForeName><Initials>RS</Initials><AffiliationInfo><Affiliation>Centre for Motor Neuron Disease Research, Macquarie Medical School, Faculty of Medicine, Health and Human Sciences, Macquarie University, Sydney, New South Wales, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Atkin</LastName><ForeName>Julie D</ForeName><Initials>JD</Initials><AffiliationInfo><Affiliation>Centre for Motor Neuron Disease Research, Macquarie Medical School, Faculty of Medicine, Health and Human Sciences, Macquarie University, Sydney, New South Wales, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Albert</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Centre for Motor Neuron Disease Research, Macquarie Medical School, Faculty of Medicine, Health and Human Sciences, Macquarie University, Sydney, New South Wales, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shi</LastName><ForeName>Bingyang</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Centre for Motor Neuron Disease Research, Macquarie Medical School, Faculty of Medicine, Health and Human Sciences, Macquarie University, Sydney, New South Wales, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blizzard</LastName><ForeName>Catherine A</ForeName><Initials>CA</Initials><Identifier Source="ORCID">0000-0002-8683-2937</Identifier><AffiliationInfo><Affiliation>Menzies Institute for Medical Research, College of Health and Medicine, University of Tasmania, Hobart, Tasmania, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morsch</LastName><ForeName>Marco</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-9484-8050</Identifier><AffiliationInfo><Affiliation>Centre for Motor Neuron Disease Research, Macquarie Medical School, Faculty of Medicine, Health and Human Sciences, Macquarie University, Sydney, New South Wales, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Walker</LastName><ForeName>Adam K</ForeName><Initials>AK</Initials><Identifier Source="ORCID">0000-0001-7954-5801</Identifier><AffiliationInfo><Affiliation>Centre for Motor Neuron Disease Research, Macquarie Medical School, Faculty of Medicine, Health and Human Sciences, Macquarie University, Sydney, New South Wales, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neurodegeneration Pathobiology Laboratory, Queensland Brain Institute, The University of Queensland, St Lucia, Queensland, Australia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>08</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>France</Country><MedlineTA>Eur J Neurosci</MedlineTA><NlmUniqueID>8918110</NlmUniqueID><ISSNLinking>0953-816X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004268">DNA-Binding Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C578077">TDP-43 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>7LJ087RS6F</RegistryNumber><NameOfSubstance UI="D019782">Riluzole</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004268" MajorTopicYN="N">DNA-Binding Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="Y">Neurodegenerative Diseases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019782" MajorTopicYN="N">Riluzole</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">AMPA receptors</Keyword><Keyword MajorTopicYN="N">motor neuron disease</Keyword><Keyword MajorTopicYN="N">muscle atrophy</Keyword><Keyword MajorTopicYN="N">neurodegeneration</Keyword><Keyword MajorTopicYN="N">pre-clinical study</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>7</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>12</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>8</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>8</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>9</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>8</Month><Day>14</Day><Hour>6</Hour><Minute>32</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34390052</ArticleId><ArticleId IdType="doi">10.1111/ejn.15422</ArticleId></ArticleIdList><ReferenceList><Title>REFERENCES</Title><Reference><Citation>Achour, A., M'Bika, J. P., &amp; Biquard, J. M. (2009). Enhanced endogenous type I interferon cell-driven survival and inhibition of spontaneous apoptosis by Riluzole. Virology, 386(1), 160-167. https://doi.org/10.1016/j.virol.2008.12.041</Citation></Reference><Reference><Citation>Albo, F., Pieri, M., &amp; Zona, C. (2004). Modulation of AMPA receptors in spinal motor neurons by the neuroprotective agent riluzole. Journal of Neuroscience Research, 78(2), 200-207. https://doi.org/10.1002/jnr.20244</Citation></Reference><Reference><Citation>Bellingham, M. C. (2011). A review of the neural mechanisms of action and clinical efficiency of riluzole in treating amyotrophic lateral sclerosis: What have we learned in the last decade? CNS Neuroscience &amp; Therapeutics, 17(1), 4-31. https://doi.org/10.1111/j.1755-5949.2009.00116.x</Citation></Reference><Reference><Citation>Bissaro, M., Federico, S., Salmaso, V., Sturlese, M., Spalluto, G., &amp; Moro, S. (2018). Targeting protein kinase CK1delta with riluzole: Could it be one of the possible missing bricks to interpret its effect in the treatment of ALS from a molecular point of view? ChemMedChem, 13(24), 2601-2605. https://doi.org/10.1002/cmdc.201800632</Citation></Reference><Reference><Citation>Bloemberg, D., &amp; Quadrilatero, J. (2012). Rapid determination of myosin heavy chain expression in rat, mouse, and human skeletal muscle using multicolor immunofluorescence analysis. PLoS ONE, 7(4), e35273. https://doi.org/10.1371/journal.pone.0035273</Citation></Reference><Reference><Citation>Bonini, D., Mora, C., Tornese, P., Sala, N., Filippini, A., La Via, L., Milanese, M., Calza, S., Bonanno, G., Racagni, G., Gennarelli, M., Popoli, M., Musazzi, L., &amp; Barbon, A. (2016). Acute footshock stress induces time-dependent modifications of AMPA/NMDA protein expression and AMPA phosphorylation. Neural Plasticity, 2016, 7267865.</Citation></Reference><Reference><Citation>Carbone, M., Duty, S., &amp; Rattray, M. (2012). Riluzole elevates GLT-1 activity and levels in striatal astrocytes. Neurochemistry International, 60(1), 31-38. https://doi.org/10.1016/j.neuint.2011.10.017</Citation></Reference><Reference><Citation>Chen, S., Liao, Q., Lu, K., Zhou, J., Huang, C., &amp; Bi, F. (2020). Riluzole exhibits no therapeutic efficacy on a transgenic rat model of amyotrophic lateral sclerosis. Current Neurovascular Research, 17(3), 275-285. https://doi.org/10.2174/1567202617666200409125227</Citation></Reference><Reference><Citation>Chiarotto, G. B., Cartarozzi, L. P., Perez, M., Biscola, N. P., Spejo, A. B., Gubert, F., Franca Junior, M., Mendez-Otero, R., &amp; de Oliveira, A. L. (2019). Tempol improves neuroinflammation and delays motor dysfunction in a mouse model (SOD1(G93A)) of ALS. Journal of Neuroinflammation, 16(1), 218. https://doi.org/10.1186/s12974-019-1598-x</Citation></Reference><Reference><Citation>de Jongh, A. D., van Eijk, R. P. A., &amp; van den Berg, L. H. (2019). Evidence for a multimodal effect of riluzole in patients with ALS? Journal of Neurology, Neurosurgery, and Psychiatry, 90(10), 1183-1184. https://doi.org/10.1136/jnnp-2018-320211</Citation></Reference><Reference><Citation>Du, J., Suzuki, K., Wei, Y., Wang, Y., Blumenthal, R., Chen, Z., Falke, C., Zarate, C. A. Jr., &amp; Manji, H. K. (2007). The anticonvulsants lamotrigine, riluzole, and valproate differentially regulate AMPA receptor membrane localization: Relationship to clinical effects in mood disorders. Neuropsychopharmacology, 32(4), 793-802. https://doi.org/10.1038/sj.npp.1301178</Citation></Reference><Reference><Citation>Dyer, M. S., Reale, L. A., Lewis, K. E., Walker, A. K., Dickson, T. C., Woodhouse, A., &amp; Blizzard, C. A. (2021). Mislocalisation of TDP-43 to the cytoplasm causes cortical hyperexcitability and reduced excitatory neurotransmission in the motor cortex. Journal of Neurochemistry, 157(4), 1300-1315. https://doi.org/10.1111/jnc.15214</Citation></Reference><Reference><Citation>Fang, T., Al Khleifat, A., Meurgey, J. H., Jones, A., Leigh, P. N., Bensimon, G., &amp; Al-Chalabi, A. (2018). Stage at which riluzole treatment prolongs survival in patients with amyotrophic lateral sclerosis: A retrospective analysis of data from a dose-ranging study. Lancet Neurology, 17(5), 416-422. https://doi.org/10.1016/S1474-4422(18)30054-1</Citation></Reference><Reference><Citation>Feldmeyer, D., Kask, K., Brusa, R., Kornau, H. C., Kolhekar, R., Rozov, A., Burnashev, N., Jensen, V., Hvalby, O., Sprengel, R., &amp; Seeburg, P. H. (1999). Neurological dysfunctions in mice expressing different levels of the Q/R site-unedited AMPAR subunit GluR-B. Nature Neuroscience, 2(1), 57-64. https://doi.org/10.1038/4561</Citation></Reference><Reference><Citation>Fumagalli, E., Funicello, M., Rauen, T., Gobbi, M., &amp; Mennini, T. (2008). Riluzole enhances the activity of glutamate transporters GLAST, GLT1 and EAAC1. European Journal of Pharmacology, 578(2-3), 171-176. https://doi.org/10.1016/j.ejphar.2007.10.023</Citation></Reference><Reference><Citation>Gallo, A., Vukic, D., Michalik, D., O'Connell, M. A., &amp; Keegan, L. P. (2017). ADAR RNA editing in human disease; more to it than meets the I. Human Genetics, 136(9), 1265-1278. https://doi.org/10.1007/s00439-017-1837-0</Citation></Reference><Reference><Citation>Ge, Y., Tian, M., Liu, L., Wong, T. P., Gong, B., Wu, D., Cho, T., Lin, S., Kast, J., Lu, J., &amp; Wang, Y. T. (2019). p97 regulates GluA1 homomeric AMPA receptor formation and plasma membrane expression. Nature Communications, 10(1), 4089. https://doi.org/10.1038/s41467-019-12096-7</Citation></Reference><Reference><Citation>Geevasinga, N., Menon, P., Ng, K., Van Den Bos, M., Byth, K., Kiernan, M. C., &amp; Vucic, S. (2016). Riluzole exerts transient modulating effects on cortical and axonal hyperexcitability in ALS. Amyotroph Lateral Scler Frontotemporal Degener, 17(7-8), 580-588. https://doi.org/10.1080/21678421.2016.1188961</Citation></Reference><Reference><Citation>Greger, I. H., Khatri, L., Kong, X., &amp; Ziff, E. B. (2003). AMPA receptor tetramerization is mediated by Q/R editing. Neuron, 40(4), 763-774. https://doi.org/10.1016/S0896-6273(03)00668-8</Citation></Reference><Reference><Citation>Gregory, J. M., Livesey, M. R., McDade, K., Selvaraj, B. T., Barton, S. K., Chandran, S., &amp; Smith, C. (2020). Dysregulation of AMPA receptor subunit expression in sporadic ALS post-mortem brain. The Journal of Pathology, 250(1), 67-78. https://doi.org/10.1002/path.5351</Citation></Reference><Reference><Citation>Gurney, M. E., Cutting, F. B., Zhai, P., Doble, A., Taylor, C. P., Andrus, P. K., &amp; Hall, E. D. (1996). Benefit of vitamin E, riluzole, and gabapentin in a transgenic model of familial amyotrophic lateral sclerosis. Annals of Neurology, 39(2), 147-157. https://doi.org/10.1002/ana.410390203</Citation></Reference><Reference><Citation>Gurney, M. E., Fleck, T. J., Himes, C. S., &amp; Hall, E. D. (1998). Riluzole preserves motor function in a transgenic model of familial amyotrophic lateral sclerosis. Neurology, 50(1), 62-66. https://doi.org/10.1212/WNL.50.1.62</Citation></Reference><Reference><Citation>Hegedus, J., Putman, C. T., Tyreman, N., &amp; Gordon, T. (2008). Preferential motor unit loss in the SOD1 G93A transgenic mouse model of amyotrophic lateral sclerosis. The Journal of Physiology, 586(14), 3337-3351. https://doi.org/10.1113/jphysiol.2007.149286</Citation></Reference><Reference><Citation>Hogg, M. C., Halang, L., Woods, I., Coughlan, K. S., &amp; Prehn, J. H. M. (2018). Riluzole does not improve lifespan or motor function in three ALS mouse models. Amyotroph Lateral Scler Frontotemporal Degener, 19(5-6), 438-445. https://doi.org/10.1080/21678421.2017.1407796</Citation></Reference><Reference><Citation>Hunsberger, H. C., Weitzner, D. S., Rudy, C. C., Hickman, J. E., Libell, E. M., Speer, R. R., Gerhardt, G. A., &amp; Reed, M. N. (2015). Riluzole rescues glutamate alterations, cognitive deficits, and tau pathology associated with P301L tau expression. Journal of Neurochemistry, 135(2), 381-394. https://doi.org/10.1111/jnc.13230</Citation></Reference><Reference><Citation>Isaac, J. T., Ashby, M. C., &amp; McBain, C. J. (2007). The role of the GluR2 subunit in AMPA receptor function and synaptic plasticity. Neuron, 54(6), 859-871. https://doi.org/10.1016/j.neuron.2007.06.001</Citation></Reference><Reference><Citation>Jablonski, M. R., Markandaiah, S. S., Jacob, D., Meng, N. J., Li, K., Gennaro, V., Lepore, A. C., Trotti, D., &amp; Pasinelli, P. (2014). Inhibiting drug efflux transporters improves efficacy of ALS therapeutics. Annals of Clinical Translational Neurology, 1(12), 996-1005. https://doi.org/10.1002/acn3.141</Citation></Reference><Reference><Citation>Jiang, K., Zhuang, Y., Yan, M., Chen, H., Ge, A. Q., Sun, L., &amp; Miao, B. (2016). Effects of riluzole on P2X7R expression in the spinal cord in rat model of neuropathic pain. Neuroscience Letters, 618, 127-133. https://doi.org/10.1016/j.neulet.2016.02.065</Citation></Reference><Reference><Citation>Jiang, T., Handley, E., Brizuela, M., Dawkins, E., Lewis, K. E. A., Clark, R. M., Dickson, T. C., &amp; Blizzard, C. A. (2019). Amyotrophic lateral sclerosis mutant TDP-43 may cause synaptic dysfunction through altered dendritic spine function. Disease Models &amp; Mechanisms, 12(5), dmm038109. https://doi.org/10.1242/dmm.038109</Citation></Reference><Reference><Citation>Klemann, C., Visser, J. E., Van Den Bosch, L., Martens, G. J. M., &amp; Poelmans, G. (2018). Integrated molecular landscape of amyotrophic lateral sclerosis provides insights into disease etiology. Brain Pathology, 28(2), 203-211. https://doi.org/10.1111/bpa.12485</Citation></Reference><Reference><Citation>Konen, L. M., Wright, A. L., Royle, G. A., Morris, G. P., Lau, B. K., Seow, P. W., Zinn, R., Milham, L. T., Vaughan, C. W., &amp; Vissel, B. (2020). A new mouse line with reduced GluA2 Q/R site RNA editing exhibits loss of dendritic spines, hippocampal CA1-neuron loss, learning and memory impairments and NMDA receptor-independent seizure vulnerability. Molecular Brain, 13(1), 27. https://doi.org/10.1186/s13041-020-0545-1</Citation></Reference><Reference><Citation>Kwong, L. K., Irwin, D. J., Walker, A. K., Xu, Y., Riddle, D. M., Trojanowski, J. Q., &amp; Lee, V. M. (2014). Novel monoclonal antibodies to normal and pathologically altered human TDP-43 proteins. Acta Neuropathologica Communications, 2, 33. https://doi.org/10.1186/2051-5960-2-33</Citation></Reference><Reference><Citation>Lacomblez, L., Bensimon, G., Leigh, P. N., Guillet, P., &amp; Meininger, V. (1996). Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Amyotrophic lateral sclerosis/riluzole study group II. Lancet, 347(9013), 1425-1431. https://doi.org/10.1016/S0140-6736(96)91680-3</Citation></Reference><Reference><Citation>Lagier-Tourenne, C., Polymenidou, M., Hutt, K. R., Vu, A. Q., Baughn, M., Huelga, S. C., Clutario, K. M., Ling, S. C., Liang, T. Y., Mazur, C., Wancewicz, E., Kim, A. S., Watt, A., Freier, S., Hicks, G. G., Donohue, J. P., Shiue, L., Bennett, C. F., Ravits, J., &#x2026; Yeo, G. W. (2012). Divergent roles of ALS-linked proteins FUS/TLS and TDP-43 intersect in processing long pre-mRNAs. Nature Neuroscience, 15(11), 1488-1497. https://doi.org/10.1038/nn.3230</Citation></Reference><Reference><Citation>Lamanauskas, N., &amp; Nistri, A. (2008). Riluzole blocks persistent Na+ and Ca2+ currents and modulates release of glutamate via presynaptic NMDA receptors on neonatal rat hypoglossal motoneurons in vitro. The European Journal of Neuroscience, 27(10), 2501-2514. https://doi.org/10.1111/j.1460-9568.2008.06211.x</Citation></Reference><Reference><Citation>Lesuis, S. L., Kaplick, P. M., Lucassen, P. J., &amp; Krugers, H. J. (2019). Treatment with the glutamate modulator riluzole prevents early life stress-induced cognitive deficits and impairments in synaptic plasticity in APPswe/PS1dE9 mice. Neuropharmacology, 150, 175-183. https://doi.org/10.1016/j.neuropharm.2019.02.023</Citation></Reference><Reference><Citation>Ling, S. C., Polymenidou, M., &amp; Cleveland, D. W. (2013). Converging mechanisms in ALS and FTD: Disrupted RNA and protein homeostasis. Neuron, 79(3), 416-438. https://doi.org/10.1016/j.neuron.2013.07.033</Citation></Reference><Reference><Citation>Liu, S. J., &amp; Zukin, R. S. (2007). Ca2+&#x2212;permeable AMPA receptors in synaptic plasticity and neuronal death. Trends in Neurosciences, 30(3), 126-134. https://doi.org/10.1016/j.tins.2007.01.006</Citation></Reference><Reference><Citation>Liu, Z., Xu, Y., Zhang, X., Miao, J., Han, J., &amp; Zhu, Z. (2019). Riluzole blocks HU210-facilitated ventral tegmental long-term depression by enhancing glutamate uptake in astrocytes. Neuroscience Letters, 704, 201-207. https://doi.org/10.1016/j.neulet.2019.04.021</Citation></Reference><Reference><Citation>Ludolph, A. C., Bendotti, C., Blaugrund, E., Chio, A., Greensmith, L., Loeffler, J. P., Mead, R., Niessen, H. G., Petri, S., Pradat, P. F., Robberecht, W., Ruegg, M., Schwalenstocker, B., Stiller, D., van den Berg, L., Vieira, F., &amp; von Horsten, S. (2010). Guidelines for preclinical animal research in ALS/MND: A consensus meeting. Amyotrophic Lateral Sclerosis, 11(1-2), 38-45. https://doi.org/10.3109/17482960903545334</Citation></Reference><Reference><Citation>Martinez-Silva, M. L., Imhoff-Manuel, R. D., Sharma, A., Heckman, C. J., Shneider, N. A., Roselli, F., Zytnicki, D., &amp; Manuel, M. (2018). Hypoexcitability precedes denervation in the large fast-contracting motor units in two unrelated mouse models of ALS. eLife, 7, e30955. https://doi.org/10.7554/eLife.30955</Citation></Reference><Reference><Citation>McCombe, P. A., &amp; Henderson, R. D. (2010). Effects of gender in amyotrophic lateral sclerosis. Gender Medicine, 7(6), 557-570. https://doi.org/10.1016/j.genm.2010.11.010</Citation></Reference><Reference><Citation>Miller, R. G., Mitchell, J. D., &amp; Moore, D. H. (2012). Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database of Systematic Reviews, 3, CD001447.</Citation></Reference><Reference><Citation>Mohamed, L. A., Markandaiah, S. S., Bonanno, S., Pasinelli, P., &amp; Trotti, D. (2019). Excess glutamate secreted from astrocytes drives upregulation of P-glycoprotein in endothelial cells in amyotrophic lateral sclerosis. Experimental Neurology, 316, 27-38. https://doi.org/10.1016/j.expneurol.2019.04.002</Citation></Reference><Reference><Citation>Moore, S., Alsop, E., Lorenzini, I., Starr, A., Rabichow, B. E., Mendez, E., Levy, J. L., Burciu, C., Reiman, R., Chew, J., Belzil, V. V., Robertson, W. D. D. J., Staats, K. A., Ichida, J. K., Petrucelli, L., van Keuren-Jensen, K., &amp; Sattler, R. (2019). ADAR2 mislocalization and widespread RNA editing aberrations in C9orf72-mediated ALS/FTD. Acta Neuropathologica, 138(1), 49-65. https://doi.org/10.1007/s00401-019-01999-w</Citation></Reference><Reference><Citation>Narayanan, R. K., Mangelsdorf, M., Panwar, A., Butler, T. J., Noakes, P. G., &amp; Wallace, R. H. (2013). Identification of RNA bound to the TDP-43 ribonucleoprotein complex in the adult mouse brain. Amyotroph Lateral Scler Frontotemporal Degener, 14(4), 252-260. https://doi.org/10.3109/21678421.2012.734520</Citation></Reference><Reference><Citation>Neumann, M., Sampathu, D. M., Kwong, L. K., Truax, A. C., Micsenyi, M. C., Chou, T. T., Bruce, J., Schuck, T., Grossman, M., Clark, C. M., McCluskey, L. F., Miller, B. L., Masliah, E., Mackenzie, I. R., Feldman, H., Feiden, W., Kretzschmar, H. A., Trojanowski, J. Q., &amp; Lee, V. M. (2006). Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science, 314(5796), 130-133. https://doi.org/10.1126/science.1134108</Citation></Reference><Reference><Citation>Nijssen, J., Comley, L. H., &amp; Hedlund, E. (2017). Motor neuron vulnerability and resistance in amyotrophic lateral sclerosis. Acta Neuropathologica, 133(6), 863-885. https://doi.org/10.1007/s00401-017-1708-8</Citation></Reference><Reference><Citation>Nonaka, T., Suzuki, G., Tanaka, Y., Kametani, F., Hirai, S., Okado, H., Miyashita, T., Saitoe, M., Akiyama, H., Masai, H., &amp; Hasegawa, M. (2016). Phosphorylation of TAR DNA-binding protein of 43 kDa (TDP-43) by truncated casein kinase 1delta triggers mislocalization and accumulation of TDP-43. The Journal of Biological Chemistry, 291(11), 5473-5483. https://doi.org/10.1074/jbc.M115.695379</Citation></Reference><Reference><Citation>Oberstadt, M., Stieler, J., Simpong, D. L., Romuss, U., Urban, N., Schaefer, M., Arendt, T., &amp; Holzer, M. (2018). TDP-43 self-interaction is modulated by redox-active compounds Auranofin, Chelerythrine and Riluzole. Scientific Reports, 8(1), 2248. https://doi.org/10.1038/s41598-018-20565-0</Citation></Reference><Reference><Citation>Pereira, A. C., Gray, J. D., Kogan, J. F., Davidson, R. L., Rubin, T. G., Okamoto, M., Morrison, J. H., &amp; McEwen, B. S. (2017). Age and Alzheimer's disease gene expression profiles reversed by the glutamate modulator riluzole. Molecular Psychiatry, 22(2), 296-305. https://doi.org/10.1038/mp.2016.33</Citation></Reference><Reference><Citation>Polymenidou, M., Lagier-Tourenne, C., Hutt, K. R., Huelga, S. C., Moran, J., Liang, T. Y., Ling, S. C., Sun, E., Wancewicz, E., Mazur, C., Kordasiewicz, H., Sedaghat, Y., Donohue, J. P., Shiue, L., Bennett, C. F., Yeo, G. W., &amp; Cleveland, D. W. (2011). Long pre-mRNA depletion and RNA missplicing contribute to neuronal vulnerability from loss of TDP-43. Nature Neuroscience, 14(4), 459-468. https://doi.org/10.1038/nn.2779</Citation></Reference><Reference><Citation>Quadri, Z., Johnson, N., Zamudio, F., Miller, A., Peters, M., Smeltzer, S., Hunt, J. B. Jr., Housley, S. B., Brown, B., Kraner, S., Norris, C. M., Nash, K., Weeber, E., Lee, D. C., &amp; Selenica, M. B. (2020). Overexpression of human wtTDP-43 causes impairment in hippocampal plasticity and behavioral deficits in CAMKII-tTa transgenic mouse model. Molecular and Cellular Neurosciences, 102, 103418. https://doi.org/10.1016/j.mcn.2019.103418</Citation></Reference><Reference><Citation>Robberecht, W., &amp; Philips, T. (2013). The changing scene of amyotrophic lateral sclerosis. Nature Reviews. Neuroscience, 14(4), 248-264. https://doi.org/10.1038/nrn3430</Citation></Reference><Reference><Citation>Rothstein, J. D., Martin, L. J., &amp; Kuncl, R. W. (1992). Decreased glutamate transport by the brain and spinal cord in amyotrophic lateral sclerosis. The New England Journal of Medicine, 326(22), 1464-1468. https://doi.org/10.1056/NEJM199205283262204</Citation></Reference><Reference><Citation>Rothstein, J. D., Tsai, G., Kuncl, R. W., Clawson, L., Cornblath, D. R., Drachman, D. B., Pestronk, A., Stauch, B. L., &amp; Coyle, J. T. (1990). Abnormal excitatory amino acid metabolism in amyotrophic lateral sclerosis. Annals of Neurology, 28(1), 18-25. https://doi.org/10.1002/ana.410280106</Citation></Reference><Reference><Citation>Rothstein, J. D., Van Kammen, M., Levey, A. I., Martin, L. J., &amp; Kuncl, R. W. (1995). Selective loss of glial glutamate transporter GLT-1 in amyotrophic lateral sclerosis. Annals of Neurology, 38(1), 73-84. https://doi.org/10.1002/ana.410380114</Citation></Reference><Reference><Citation>Sasaki, S., Yamashita, T., &amp; Kwak, S. (2015). Autophagy in spinal motor neurons of conditional ADAR2-knockout mice: An implication for a role of calcium in increased autophagy flux in ALS. Neuroscience Letters, 598, 79-84. https://doi.org/10.1016/j.neulet.2015.05.025</Citation></Reference><Reference><Citation>Scott, S., Kranz, J. E., Cole, J., Lincecum, J. M., Thompson, K., Kelly, N., Bostrom, A., Theodoss, J., Al-Nakhala, B. M., Vieira, F. G., Ramasubbu, J., &amp; Heywood, J. A. (2008). Design, power, and interpretation of studies in the standard murine model of ALS. Amyotrophic Lateral Sclerosis, 9(1), 4-15. https://doi.org/10.1080/17482960701856300</Citation></Reference><Reference><Citation>Sephton, C. F., Cenik, C., Kucukural, A., Dammer, E. B., Cenik, B., Han, Y., Dewey, C. M., Roth, F. P., Herz, J., Peng, J., Moore, M. J., &amp; Yu, G. (2011). Identification of neuronal RNA targets of TDP-43-containing ribonucleoprotein complexes. The Journal of Biological Chemistry, 286(2), 1204-1215. https://doi.org/10.1074/jbc.M110.190884</Citation></Reference><Reference><Citation>Shaw, M. P., Higginbottom, A., McGown, A., Castelli, L. M., James, E., Hautbergue, G. M., Shaw, P. J., &amp; Ramesh, T. M. (2018). Stable transgenic C9orf72 zebrafish model key aspects of the ALS/FTD phenotype and reveal novel pathological features. Acta Neuropathologica Communications, 6(1), 125. https://doi.org/10.1186/s40478-018-0629-7</Citation></Reference><Reference><Citation>Spiller, K. J., Cheung, C. J., Restrepo, C. R., Kwong, L. K., Stieber, A. M., Trojanowski, J. Q., &amp; Lee, V. M. (2016). Selective motor neuron resistance and recovery in a new inducible mouse model of TDP-43 proteinopathy. The Journal of Neuroscience, 36(29), 7707-7717. https://doi.org/10.1523/JNEUROSCI.1457-16.2016</Citation></Reference><Reference><Citation>Spiller, K. J., Khan, T., Dominique, M. A., Restrepo, C. R., Cotton-Samuel, D., Levitan, M., Jafar-Nejad, P., Zhang, B., Soriano, A., Rigo, F., Trojanowski, J. Q., &amp; Lee, V. M. (2019). Reduction of matrix metalloproteinase 9 (MMP-9) protects motor neurons from TDP-43-triggered death in rNLS8 mice. Neurobiology of Disease, 124, 133-140. https://doi.org/10.1016/j.nbd.2018.11.013</Citation></Reference><Reference><Citation>Spiller, K. J., Restrepo, C. R., Khan, T., Dominique, M. A., Fang, T. C., Canter, R. G., Roberts, C. J., Miller, K. R., Ransohoff, R. M., Trojanowski, J. Q., &amp; Lee, V. M. (2018). Microglia-mediated recovery from ALS-relevant motor neuron degeneration in a mouse model of TDP-43 proteinopathy. Nature Neuroscience, 21(3), 329-340. https://doi.org/10.1038/s41593-018-0083-7</Citation></Reference><Reference><Citation>Svahn, A. J., Don, E. K., Badrock, A. P., Cole, N. J., Graeber, M. B., Yerbury, J. J., Chung, R., &amp; Morsch, M. (2018). Nucleo-cytoplasmic transport of TDP-43 studied in real time: Impaired microglia function leads to axonal spreading of TDP-43 in degenerating motor neurons. Acta Neuropathologica, 136(3), 445-459. https://doi.org/10.1007/s00401-018-1875-2</Citation></Reference><Reference><Citation>Tollervey, J. R., Curk, T., Rogelj, B., Briese, M., Cereda, M., Kayikci, M., Konig, J., Hortobagyi, T., Nishimura, A. L., Zupunski, V., Patani, R., Chandran, S., Rot, G., Zupan, B., Shaw, C. E., &amp; Ule, J. (2011). Characterizing the RNA targets and position-dependent splicing regulation by TDP-43. Nature Neuroscience, 14(4), 452-458. https://doi.org/10.1038/nn.2778</Citation></Reference><Reference><Citation>Urbani, A., &amp; Belluzzi, O. (2000). Riluzole inhibits the persistent sodium current in mammalian CNS neurons. The European Journal of Neuroscience, 12(10), 3567-3574. https://doi.org/10.1046/j.1460-9568.2000.00242.x</Citation></Reference><Reference><Citation>Walker, A. K., Spiller, K. J., Ge, G., Zheng, A., Xu, Y., Zhou, M., Tripathy, K., Kwong, L. K., Trojanowski, J. Q., &amp; Lee, V. M. (2015). Functional recovery in new mouse models of ALS/FTLD after clearance of pathological cytoplasmic TDP-43. Acta Neuropathologica, 130(5), 643-660. https://doi.org/10.1007/s00401-015-1460-x</Citation></Reference><Reference><Citation>Wang, P., Wander, C. M., Yuan, C. X., Bereman, M. S., &amp; Cohen, T. J. (2017). Acetylation-induced TDP-43 pathology is suppressed by an HSF1-dependent chaperone program. Nature Communications, 8(1), 82. https://doi.org/10.1038/s41467-017-00088-4</Citation></Reference><Reference><Citation>Weskamp, K., Tank, E. M., Miguez, R., McBride, J. P., Gomez, N. B., White, M., Lin, Z., Gonzalez, C. M., Serio, A., Sreedharan, J., &amp; Barmada, S. J. (2020). Shortened TDP43 isoforms upregulated by neuronal hyperactivity drive TDP43 pathology in ALS. The Journal of Clinical Investigation, 130(3), 1139-1155. https://doi.org/10.1172/JCI130988</Citation></Reference><Reference><Citation>Wright, A., &amp; Vissel, B. (2012). The essential role of AMPA receptor GluR2 subunit RNA editing in the normal and diseased brain. Frontiers in Molecular Neuroscience, 5, 34.</Citation></Reference><Reference><Citation>Wu, Q., Zhang, Y., Zhang, Y., Zhang, W., Zhang, W., Liu, Y., Xu, S., Guan, Y., &amp; Chen, X. (2020). Riluzole improves functional recovery after acute spinal cord injury in rats and may be associated with changes in spinal microglia/macrophages polarization. Neuroscience Letters, 723, 134829. https://doi.org/10.1016/j.neulet.2020.134829</Citation></Reference><Reference><Citation>Yamashita, T., Chai, H. L., Teramoto, S., Tsuji, S., Shimazaki, K., Muramatsu, S., &amp; Kwak, S. (2013). Rescue of amyotrophic lateral sclerosis phenotype in a mouse model by intravenous AAV9-ADAR2 delivery to motor neurons. EMBO Molecular Medicine, 5(11), 1710-1719. https://doi.org/10.1002/emmm.201302935</Citation></Reference><Reference><Citation>Yamashita, T., &amp; Kwak, S. (2019). Cell death cascade and molecular therapy in ADAR2-deficient motor neurons of ALS. Neuroscience Research, 144, 4-13. https://doi.org/10.1016/j.neures.2018.06.004</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>